Replies to post #544581 on NorthWest Biotherapeutics Inc (NWBO)

[Larppis]

Yes, we don't know that.

[exwannabe]

From looking at the trial, do we know how many are GBM, and how many of the GBM are included in the 60%? Looks like they are allowing other types of gliomas

You are missing up the 2 trial.

The poly ICLC trial is the one that enrolled grade 3 and 4 gliomas. We do not know the breakdown, but it was reported that grade 3 lived longer than GBM (not very surprising).

The "Keytruada" combo trial is the one that reported 60% 2 year OS on a handful of patients. That was all rGBM and also used Poly-ICLC.